Georgetown researchers tested talabostat (also known as BXCL701) alone and alongside a treatment that inhibits the immune checkpoint PD-1 in mouse models of pancreatic cancer. Both treatments slowed tumor growth, and the combination significantly increased the recruitment of cancer-fighting immune cells, the researchers reported in the Journal for ImmunoTherapy of Cancer.